Harmony CCO awarded options and RSUs

Harmony Biosciences Holdings, Inc. reported an insider equity grant to its Chief Commercial Officer, Adam H. Zaeske.

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. reported an insider equity grant to its Chief Commercial Officer, Adam H. Zaeske. On January 22, 2026, he received a stock option covering 56,900 shares of common stock at an exercise price of $36.76 per share, expiring on January 22, 2036.

The option vests 25% on January 22, 2027, with the remaining shares vesting quarterly until the fourth anniversary of the grant date, subject to continued service. On the same date, Zaeske was also granted 16,200 restricted stock units, which vest in four equal annual installments beginning January 22, 2027, each representing one share of common stock.

Insider Trade Summary

Grant/Award: 73,100 shares

Grant/Award 2 txns

Insider Zaeske Adam H.

Role CHIEF COMMERCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	56,900	$0.00	$0.00
Grant/Award	Restricted Stock Units	16,200	$0.00	$0.00

Holdings After Transaction: Stock Option — 56,900 contracts (Direct); Restricted Stock Units — 16,200 contracts (Direct)

Footnotes (2)

1. F1. The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
2. F2. The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Harmony Biosciences (HRMY) report for its CCO?

The filing reports that Chief Commercial Officer Adam H. Zaeske received a grant of 56,900 stock options and 16,200 restricted stock units on January 22, 2026.

What are the key terms of the Harmony Biosciences CCO stock option grant?

The CCO received a stock option for 56,900 shares with an exercise price of $36.76 per share, expiring on January 22, 2036.

How do the 56,900 Harmony Biosciences stock options vest for the CCO?

The option vests 25% on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis until the fourth anniversary of the grant date, subject to continued service.

What are the vesting terms of the 16,200 Harmony Biosciences RSUs granted to the CCO?

The 16,200 restricted stock units vest in four equal annual installments beginning on January 22, 2027, subject to the CCO’s continued service.

How many derivative securities does the Harmony Biosciences CCO hold after this Form 4?

After these awards, the CCO beneficially owns 56,900 stock options and 16,200 restricted stock units, all reported as direct ownership.

What does each Harmony Biosciences restricted stock unit represent in this Form 4?

Each restricted stock unit represents a contingent right to receive one share of Harmony Biosciences common stock and has no expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 04:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zaeske Adam H.

(Last) (First) (Middle)

C/O HARMONY BIOSCIENCES HOLDINGS, INC.

(Street)

PLYMOUTH MEETING PA 19462

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF COMMERCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$36.76	01/22/2026		A		56,900		(1)	01/22/2036	Common Stock	56,900	$0	56,900	D
Restricted Stock Units	(2)	01/22/2026		A		16,200		(2)	(2)	Common Stock	16,200	$0	16,200	D

Explanation of Responses:

1. The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

2. The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.

	/s/ Christian Ulrich, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.